Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$106.00K$106.00Kderived+34.2% vs Q4 2021 Net Income-$3.03M-$3.03MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,018,000N/M Operating Cash Flowderived-$2,997,000N/M Free Cash Flowderived-$2,999,000N/M Margins · derivedOperating margin-2847.2%+1533.8 pt vs Q4 2021
Net margin-2856.6%+1524.4 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 29, 2023 · 88 d after period end